Chemicals

Genentech’s troubles highlight biosimilar trade secret risks

Two founders of JHL Biotech have recently been indicted for conspiracy to steal trade secrets from the Californian company, while two other individuals pleaded guilty to similar charges

Genentech’s troubles highlight biosimilar trade secret risks
Biopharma M&A has fallen off a cliff – but IP owners in the sector have reasons to be cheerful
20 Jul 2021

Biopharma M&A has fallen off a cliff – but IP owners in the sector have reasons to be cheerful

The number and value of acquisitions have both tumbled further than in the early months of 2020

Biden’s march-in rights reversal is further evidence of US policy shift on pharma IP rights
16 Jul 2021

Biden’s march-in rights reversal is further evidence of US policy shift on pharma IP rights

US president abandons Trump-era proposal to rule out patent suspensions under the Bayh-Dole Act

Latest

View all
15 Jul 2021

China’s patent linkage system is finally up and running

What the final implementing measures of the Hatch-Waxman-style framework mean for biopharma patentees and generics Read more

8 Jul 2021

New SPC data demonstrates the commercial power of patent extension rights in Europe

A recent report into supplementary protection certificates provides crucial insights for IP strategists and policy-makers Read more

7 Jul 2021

UK Supreme Court quashes £220 million third-party lawsuit against patent litigant

Country’s National Health Service fails to overturn rules on damages sought by healthcare providers affected by failed enforcement Read more

1 Jul 2021

Everything you need to know about SCOTUS’ Minerva ruling on assignor estoppel

In a 5-4 decision the court’s justices significantly narrowed the scope of the doctrine that prevents assignors from challenging patents in court. Read more

News

View all
15 Feb 2021

Uptrend in oppositions could spell costly delays for Indian patent applicants

Practitioners say greater attention to detail during the prosecution process can head off frivolous challenges Read more

15 Dec 2020

East Asian giants leave their stamp on the IP market

IAM reveals the Asia IP Elite members for 2020 from two dynamic high-tech jurisdictions: South Korea and Taiwan Read more

14 Dec 2020

The Asia IP Elite – a shared commitment to excellence across very different markets

IAM reveals the top in-house IP teams from India, Southeast Asia and Australasia Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

Analysis

View all
17 Jun 2021

Another startup taps Aon for insurance-backed IP financing

Insurance giant, which recently announced a $400m IP fund, says it has a strong pipeline of lending deals in the works Read more

16 Jun 2021

Tesla transactions show that patents matter in research collaboration and M&A

Recent recordals show the electric car maker has cut a deal with Panasonic, assimilated a large portfolio of solar rights and gained assets via M&A deals Read more

11 May 2021

Brazilian Supreme Court set to decide whether tens of thousands of patents live or die

Up to 30,000 individual grants are at risk as the country’s highest court decides whether to retroactively apply a landmark ruling it handed down last week Read more

6 May 2021

Biden backs covid-19 IP waiver in historic US policy shift

Landmark move suggests realignment in America’s domestic and international healthcare IP stance Read more

Insights

View all
12 Aug 2020

IP market news highlights

A rundown of some of the top news stories on the IAM platform in May, June and July Read more

12 Aug 2020

As the fallout from covid continues, the two IP superpowers offer different messages

While China cheers an uptick in applications, the USPTO warns of a prolonged downturn Read more

8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more